首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RETNLb |
| Uniprot No | Q9BQ08 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-111aa |
| 氨基酸序列 | MGPSSCLLLILIPLLQLINPGSTQCSLDSVMDKKIKDVLNSLEYSPSPISKKLSCASVKSQGRPSSCPAGMAVTGCACGYGCGSWDVQLETTCHCQCSVVDWTTARCCHLT |
| 预测分子量 | 11,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RETNLb(Resistin-like molecule beta)重组蛋白的3篇参考文献示例(注：内容为示例性概括，实际文献请根据具体研究验证)：
1. **文献名称**: *"Recombinant Resistin-like molecule beta induces murine airway hyperresponsiveness"*
**作者**: Munitz A, et al.
**摘要**: 研究利用重组RETNLb蛋白处理小鼠模型，发现其通过激活TLR4信号通路促进Th2型炎症反应，导致气道高反应性，提示RETNLb在哮喘发病中的潜在作用。
2. **文献名称**: *"Expression and purification of bioactive human RETNLb in E. coli"*
**作者**: Lee SJ, et al.
**摘要**: 报道了一种通过大肠杆菌表达系统高效制备可溶性重组人源RETNLb蛋白的方法，并验证其通过抑制胰岛素受体通路影响脂肪细胞葡萄糖摄取的功能活性。
3. **文献名称**: *"RETNLb recombinant protein exacerbates colonic inflammation in DSS-induced colitis"*
**作者**: Park CY, et al.
**摘要**: 实验表明腹腔注射重组RETNLb蛋白可通过上调IL-6和TNF-α表达加重结肠炎小鼠模型的黏膜损伤，提示其作为炎症性肠病治疗靶点的可能性。
注：以上为基于RETNLb已知功能的模拟文献概括，实际研究需查阅具体数据库(如PubMed)。建议以关键词“RETNLb recombinant”或“RELMB recombinant”检索最新文献。
RETNLb (Resistin-like molecule beta), also known as FIZZ2 (Found in inflammatory zone 2), is a cysteine-rich secretory protein belonging to the resistin family. Initially identified for its role in metabolic and inflammatory processes, RETNLb has garnered attention for its tissue-specific expression and regulatory functions. It shares structural homology with other resistin family members, featuring a conserved C-terminal domain critical for protein interactions. Unlike resistin, which is linked to insulin resistance, RETNLb is highly expressed in intestinal epithelial cells, particularly in the colon, suggesting a specialized role in mucosal immunity and gut homeostasis.
Research highlights its involvement in modulating innate immune responses and maintaining intestinal barrier integrity. RETNLb is upregulated during intestinal inflammation, infections, or tissue damage, where it appears to regulate goblet cell function and mucus secretion—key components of gut defense. Studies in murine models indicate its protective effects in colitis and its interaction with pathogen-associated molecular patterns (PAMPs). However, its precise signaling mechanisms remain unclear, with proposed receptors including TLR4 or other pattern recognition receptors.
The recombinant RETNLb protein, typically produced in *E. coli* or mammalian expression systems, enables functional studies by providing a purified, bioactive form. Its applications span *in vitro* assays (e.g., immune cell activation, epithelial barrier models) and *in vivo* disease modeling. Recent interest focuses on its dual role in inflammation: promoting tissue repair while potentially exacerbating chronic inflammatory states. Additionally, RETNLb’s implication in metabolic disorders and cancer progression underscores its therapeutic relevance. Recombinant variants are also used to dissect structure-function relationships, aiding drug development for conditions like inflammatory bowel disease or metabolic syndrome. Despite progress, challenges persist in elucidating receptor interactions and context-dependent signaling pathways.
×
